Explore

Cancer Research 2019

7th Edition of World Congress on Cancer Research, Survivorship and Management 2019

Japan, United Kingdom
22 - 23 August 2019
The conference ended on 23 August 2019

Important Dates

Abstract Acceptance Notification
13th June 2019
Abstract Submission Deadline
26th June 2019
Early Bird Deadline
26th June 2019
Final Abstract / Full Paper Deadline
1st August 2019

About Cancer Research 2019

Euroscicon Ltd welcomes you to participate at Cancer Research 2019, that goes for uniting the teachers, scientists, clinicians, instructors, program engineers to give a worldwide gathering to the spread of unique research results, new thoughts and viable advancement encounters which focus on both hypothesis and practices in our Therapeutic gatherings. The gathering will be on August 22-23, 2019 in Tokyo, Japan. The conference is CME & CPD Accredited.

Topics

Cancer, Cancer biology

Call for Papers

Euroscicon Ltd welcomes you to participate at Cancer Research 2019, that goes for uniting the teachers, scientists, clinicians, instructors, program engineers to give a worldwide gathering to the spread of unique research results, new thoughts and viable advancement encounters which focus on both hypothesis and practices in our Therapeutic gatherings. The gathering will be on August 22-23, 2019 in Tokyo, Japan. The conference is CME & CPD Accredited.

It is our most prominent joy to welcome you to the official site of Cancer Research 2019, that goes for uniting the teachers, scientists, clinicians, instructors, program engineers to give a worldwide gathering to the spread of unique research results, new thoughts and viable advancement encounters which focus on both hypothesis and practices in our Therapeutic gatherings. The gathering will be on August 22-23, 2019 in Tokyo, Japan. The subject of the gathering is near, "Rising and Imaginative methodologies for the progression of disease treatment. The disease is a harmful development or a tumor coming about because of an uncontrolled division of cells. Malignancy is the second most regular reason for death in the European Association. Malignancy of the bosom and lung tumors is the main growth composes in European guys and females. The weight of new growth cases in 2010 was assessed to associate with 3 million, in European areas to 53% of this heap. The weight of tumor is expanding worldwide regardless of advances in growth finding and treatment. Notwithstanding, the overall growth insights delineate that 1 million grown-ups on the planet were determined to have the disease and 1.7million passings happened in 2012 in Europe and 7.4 million internationally.

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.